首页> 美国卫生研究院文献>International Journal of Oncology >New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane
【2h】

New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane

机译:抗芳香化酶抑制剂乳腺癌的新细胞培养模型显示出对氟维司群治疗的敏感性以及来曲唑和依西美坦之间的交叉耐药性

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Aromatase inhibitor (AI) treatment is first-line systemic treatment for the majority of postmenopausal breast cancer patients with estrogen receptor (ER)-positive primary tumor. Although many patients benefit from treatment, some will develop resistance, and models mimicking acquired resistance will be valuable tools to unravel the resistance mechanisms and to find new treatments and biomarkers. Cell culture models for acquired resistance to the three clinically relevant AIs letrozole, anastrozole and exemestane were developed by selection and expansion of colonies of MCF-7 breast cancer cells surviving long-term AI treatment under conditions where endogenous aromatase-mediated conversion of androgen to estrogen was required for growth. Four cell lines resistant to each of the AIs were established and characterized. Maintenance of ER expression and function was a general finding, but ER loss was seen in one of twelve cell lines. HER receptor expression was increased, in particular EGFR expression in letrozole-resistant cell lines. The AI-resistant cell lines had acquired ability to grow without aromatase-mediated conversion of testosterone to estradiol, but upon withdrawal of AI treatment, testosterone induced minor growth stimulation. Letrozole, exemestane and tamoxifen were able to abrogate the testosterone stimulation but could not reduce growth to below the level in standard growth medium with AI, demonstrating cross-resistance between letrozole, exemestane and tamoxifen. In contrast, fulvestrant totally blocked growth of the AI resistant cell lines both after withdrawal of AI and with AI treatment. These data show that ER is the main driver of growth of the AI-resistant cell lines and indicate ligand-independent activation of ER. Fulvestrant is an efficient treatment option for these AI-resistant breast cancer cells, and the cell lines will be useful tools to disclose the underlying molecular mechanism for resistance to the different AIs.
机译:芳香酶抑制剂(AI)治疗是绝经后绝大部分患有雌激素受体(ER)阳性原发性肿瘤的乳腺癌患者的一线全身治疗。尽管许多患者可以从治疗中受益,但有些患者会产生耐药性,模仿获得性耐药性的模型将成为揭示耐药性机制并寻找新疗法和生物标记物的有价值的工具。通过选择和扩大在长期内源芳香化酶介导的雄激素转化为雌激素的条件下存活了长期AI治疗的MCF-7乳腺癌细胞的集落,建立了对三种临床相关的AI来曲唑,阿那曲唑和依西美坦耐药的获得性细胞培养模型是增长所必需的。建立并鉴定了对每个AI具有抗性的四个细胞系。维持ER表达和功能是一个普遍发现,但是在12种细胞系之一中发现ER丢失。在耐来曲唑的细胞系中,HER受体表达增加,特别是EGFR表达增加。抗AI的细胞系已获得生长的能力,而无需芳香化酶介导的睾丸激素向雌二醇的转化,但在撤消AI处理后,睾丸激素诱导了较小的生长刺激。来曲唑,依西美坦和他莫昔芬能够消除睾丸激素的刺激,但不能将其生长降低到标准AI培养基中的水平以下,证明来曲唑,依西美坦和他莫昔芬之间具有交叉耐药性。相比之下,氟维司群在AI停用和AI治疗后均完全阻断了AI耐药细胞系的生长。这些数据表明ER是AI抗性细胞系生长的主要驱动力,并表明ER的配体非依赖性激活。 Fulvestrant是这些对AI耐药的乳腺癌细胞的有效治疗选择,并且这些细胞系将成为揭示针对不同AI的潜在分子机制的有用工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号